 |
Journal articles
Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment
Abstract : Cladribine is an oral synthetic purine analog that depletes lymphocytes and induces a dose-dependent reduction of T and B cells. It was approved for the therapy of highly active relapsing-remitting multiple sclerosis. Given cladribine's mechanism of action, an increased risk of malignancies was suspected from the number of cancers that occurred in the 3.5 mg/kg-treated arm (CLARITY study). We showed that cladribine inhibits cell proliferation on three melanoma cell lines tested, irrespectively of their mutational oncogenic status and invasive/metastatic potential. Aggregated safety data demonstrated that the risk of melanoma is not confirmed.
Cited literature [9 references]
https://www.hal.inserm.fr/inserm-02914268
Contributor : Sophie Tartare-Deckert Connect in order to contact the contributor
Submitted on : Tuesday, August 11, 2020 - 3:12:46 PM
Last modification on : Tuesday, June 22, 2021 - 6:06:01 PM
Long-term archiving on: : Monday, November 30, 2020 - 6:22:10 PM
Contributor : Sophie Tartare-Deckert Connect in order to contact the contributor
Submitted on : Tuesday, August 11, 2020 - 3:12:46 PM
Last modification on : Tuesday, June 22, 2021 - 6:06:01 PM
Long-term archiving on: : Monday, November 30, 2020 - 6:22:10 PM
File
Lebrun-Frenay2020_Article_Effe...
Publication funded by an institution